Page 1

ASX Announcement Quarterly Cash Flow Statement & Operational Highlights Recce Pharmaceuticals recce.com.au ACN 124 849 065 Highlights : • • Strong cash position of $ 20.87 million Topical Phase I / II Clinical Trial began and was registered on Australia New Zealand Clinical Trial Registry • R327 Sinusitis efficacy in Special Access Scheme Category A human case • • > 99.9 % effective against full suite of ESKAPE pathogens - only known antibiotic in clinical development efficacious against all ESKAPE pathogens R327 advances to Stage 2 in Australian government SARS - CoV - 2 Program R327 - Demonstrates World First Multiple Mechanisms of Action SYDNEY Australia , 30 July 2021 : Recce Pharmaceuticals Ltd ( ASX : RCE , FSE : R9Q ) , the Company developing New Classes of Synthetic Anti - infectives , today released its June 2021 quarter results and operational highlights . Financial Update The Company ended the quarter with a cash balance of $ 20.87 million . Net cash out- flows were ( $ 1.99 million ) , significantly offset by R & D rebates , grants and other state / federal initiatives . Research and Development ( $ 1.03 million ) was the largest item of expenditure . Payments to related parties ( Executive & Director fees ) was ( $ 0.342 million ) . Operational Highlights Topical Phase I / II Clinical Trial began and was registered on Australia New Zealand Clinical Trial Registry Phase I / II Topical Burns Study in Humans was registered on the Australia New Zealand Clinical Trials Registry ( ANZCTR ) under the trial ID ACTRN12621000412831 : ' Proof of Concept Study of RECCE 327 Topical Antibiotic Therapy for Infected Burn Wounds in Adults ' . ASX : RCE , FSE : R9Q Head Office : Level 25 , 88 Phillip Street , Aurora Place , SYDNEY NSW 2000 T +61 ( 02 ) 9256 2571 R & D Centre - Perth : Suite 10 , 3 Brodie Hall Drive , Technology Park , BENTLEY WA 6102 T +61 ( 8 ) 9362 9860 Washington Office : 1717 Pennsylvania Avenue NW , Suite 1025 , WASHINGTON DC 20006 USA